Side Effects and Perceptions Following Sinopharm COVID-19 Vaccination

Overview

Journal Int J Infect Dis

Publisher Elsevier

Specialty Infectious Diseases

Date 2021 Aug 13

PMID 34384899

Citations 112

Authors

Balsam Qubais Saeed

Rula Al-Shahrabi

Shaikha Salah Alhaj

Zainab Mansour Alkokhardi

Ahmed Omar Adrees

Affiliations

Soon will be listed here.

Abstract

Objectives: Vaccines are one of the best interventions developed for eradicating COVID-19. This study aimed to provide evidence on Sinopharm COVID-19 vaccine side effects.

Methods: A cross-sectional survey study was conducted between January and April 2021 to collect data on the effects of the COVID-19 vaccine among individuals in the United Arab Emirates. Demographic data, vaccination and the response of people unwilling to take the COVID-19 vaccine were reported.

Results: Side effects post first vaccine dose of normal injection site pain, fatigue and headache were more common in participants aged ≤49 years versus >49 years, while pain at the vaccination site, fatigue, lethargy, headache and tenderness were the most common side effects post second dose in both groups. All side effects for both doses were more prevalent among participants aged ≤49 years. Side effects were more common in females compared with males for both doses. The most common reason for being unwilling to take the COVID-19 vaccine was that vaccines are not effective.

Conclusion: Post-vaccination side effects for the first and second doses were mild and predictable, and there were no hospitalization cases; this data will help reduce vaccine hesitancy.

Citing Articles

Sexual dimorphism in immunity and longevity among the oldest old.

Arakelyan N, Kupriyanova D, Vasilevska J, Rogaev E Front Immunol. 2025; 16:1525948.

PMID: 40034689 PMC: 11872714. DOI: 10.3389/fimmu.2025.1525948.

Side Effects of COVID-19 Vaccination Following First and Second Doses: A Cross-Sectional Survey Based on Vaccine-associated Factors.

Tavakkoli S, Rostami Nejad M, Pourhoseingholi M, Mirmomeni G, Ghorbani F, Rezaei Tavirani M Tanaffos. 2025; 23(2):115-128.

PMID: 39959795 PMC: 11825075.

Comparing COVID-19 literacy and vaccine hesitancy among health care workers, including oral health professionals, in Japan.

Ueno F, Haresaku S, Iino H, Taguchi T, Sakagami R, Matsumoto K BDJ Open. 2025; 11(1):1.

PMID: 39755681 PMC: 11700177. DOI: 10.1038/s41405-024-00282-9.

Immunogenicity of two-dose sinopharm BBIB-CorV vaccine in Morocco: One-year follow-up and neutralizing activity against severe acute respiratory syndrome coronavirus 2 variants of concern.

Ouarab M, Bouaiti E, Rhazzar Z, Annaz H, Kochri S, Hemlali M Immun Inflamm Dis. 2024; 12(11):e1359.

PMID: 39530285 PMC: 11555486. DOI: 10.1002/iid3.1359.

COVID-19 vaccinations and their side effects: a scoping systematic review.

Monadhel H, Abbas A, Mohammed A F1000Res. 2024; 12:604.

PMID: 39512911 PMC: 11541072. DOI: 10.12688/f1000research.134171.2.

References

Riad A, Abdulqader H, Morgado M, Domnori S, Koscik M, Mendes J . Global Prevalence and Drivers of Dental Students' COVID-19 Vaccine Hesitancy. Vaccines (Basel). 2021; 9(6). PMC: 8226539. DOI: 10.3390/vaccines9060566. View

Kadali R, Janagama R, Peruru S, Malayala S . Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis. 2021; 106:376-381. PMC: 8049195. DOI: 10.1016/j.ijid.2021.04.047. View

Klein S, Jedlicka A, Pekosz A . The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. 2010; 10(5):338-49. PMC: 6467501. DOI: 10.1016/S1473-3099(10)70049-9. View

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007; 370(9596):1453-7. DOI: 10.1016/S0140-6736(07)61602-X. View

Habas K, Nganwuchu C, Shahzad F, Gopalan R, Haque M, Rahman S . Resolution of coronavirus disease 2019 (COVID-19). Expert Rev Anti Infect Ther. 2020; 18(12):1201-1211. DOI: 10.1080/14787210.2020.1797487. View

Petousis-Harris H . Correction to: Assessing the Safety of COVID-19 Vaccines: A Primer. Drug Saf. 2021; 44(4):507. PMC: 7884968. DOI: 10.1007/s40264-020-01023-1. View

El-Shitany N, Harakeh S, Badr-Eldin S, Bagher A, Eid B, Almukadi H . Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study. Int J Gen Med. 2021; 14:1389-1401. PMC: 8068468. DOI: 10.2147/IJGM.S310497. View

. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20):2191-4. DOI: 10.1001/jama.2013.281053. View

Klein S, Pekosz A . Sex-based biology and the rational design of influenza vaccination strategies. J Infect Dis. 2014; 209 Suppl 3:S114-9. PMC: 4157517. DOI: 10.1093/infdis/jiu066. View

10.

Riad A, Pokorna A, Attia S, Klugarova J, Koscik M, Klugar M . Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. J Clin Med. 2021; 10(7). PMC: 8037149. DOI: 10.3390/jcm10071428. View

11.

Riad A, Sagiroglu D, Ustun B, Pokorna A, Klugarova J, Attia S . Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey. J Clin Med. 2021; 10(12). PMC: 8232682. DOI: 10.3390/jcm10122629. View

12.

Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P . Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021; 21(7):939-949. PMC: 8078878. DOI: 10.1016/S1473-3099(21)00224-3. View

13.

Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z . Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020; 324(10):951-960. PMC: 7426884. DOI: 10.1001/jama.2020.15543. View

14.

Forni G, Mantovani A . COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021; 28(2):626-639. PMC: 7818063. DOI: 10.1038/s41418-020-00720-9. View

15.

McHugh M . Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012; 22(3):276-82. PMC: 3900052. View

16.

Cyranoski D . Arab nations first to approve Chinese COVID vaccine - despite lack of public data. Nature. 2020; 588(7839):548. DOI: 10.1038/d41586-020-03563-z. View

17.

Chapin-Bardales J, Gee J, Myers T . Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines. JAMA. 2021; 325(21):2201-2202. DOI: 10.1001/jama.2021.5374. View

18.

Lai C, Shih T, Ko W, Tang H, Hsueh P . Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020; 55(3):105924. PMC: 7127800. DOI: 10.1016/j.ijantimicag.2020.105924. View

19.

Haidere M, Ratan Z, Nowroz S, Zaman S, Jung Y, Hosseinzadeh H . COVID-19 Vaccine: Critical Questions with Complicated Answers. Biomol Ther (Seoul). 2020; 29(1):1-10. PMC: 7771841. DOI: 10.4062/biomolther.2020.178. View

20.

Sharma O, Sultan A, Ding H, Triggle C . A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol. 2020; 11:585354. PMC: 7591699. DOI: 10.3389/fimmu.2020.585354. View